Lv3
203 积分 2021-07-14 加入
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
4天前
已完结
Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
19天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
20天前
已完结
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
1个月前
已完结
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
1个月前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
1个月前
已关闭
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
2个月前
已完结
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
2个月前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
3个月前
已完结
Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
3个月前
已完结
皖公网安备34019202002308
